Phase II escalation study of sorafenib in patients with advanced renal cell carcinoma who progressed after routine dosage of sorafenib

Trial Profile

Phase II escalation study of sorafenib in patients with advanced renal cell carcinoma who progressed after routine dosage of sorafenib

Recruiting
Phase of Trial: Phase II

Latest Information Update: 21 May 2012

At a glance

  • Drugs Sorafenib (Primary) ; Everolimus; Sunitinib
  • Indications Renal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 Apr 2012 Planned number of patients changed to 140.
    • 17 Apr 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top